BX Contracts Monday, November 16, 2026 0.00 Neutral

Blackstone Life Sciences To Provide Johnson & Johnson With $750M In R&D Funding To Support Phase 3 Clinical Development Of OLN324, An Investigational Therapy For Serious Retinal Vascular Diseases

Blackstone Life Sciences To Provide Johnson & Johnson With $750M In R&D Funding To Support Phase 3 Clinical Development Of OLN324, An Investigational Therapy For Serious Retinal Vascular Diseases

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed